Medigen Biotechnology (3176) — Long-term Investment Intensity
Medigen Biotechnology (3176) has a Long-term Investment Intensity of 5.3% as of September 2019. Long-term investments of NT$240.59 Million represent 5.3% of total assets of NT$4.54 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Medigen Biotechnology asset resilience ratio to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Medigen Biotechnology Long-term Investment Intensity (2015–2018)
This chart shows how Medigen Biotechnology's Long-term Investment Intensity has evolved across 4 annual periods from 2015 to 2018. As of September 2019, the intensity stands at 5.3%, reflecting long-term investments of NT$240.59 Million against total assets of NT$4.54 Billion TWD. For the complete balance sheet picture, see Medigen Biotechnology assets under control.
Annual Long-term Investment Intensity for Medigen Biotechnology (2015–2018)
The table below presents the year-by-year Long-term Investment Intensity for Medigen Biotechnology from 2015 to 2018, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read how much debt does Medigen Biotechnology carry for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (TWD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2018 | 0.6% | NT$26.93 Million | NT$4.60 Billion | ▲ +0.2 pp |
| 2017 | 0.4% | NT$19.56 Million | NT$4.87 Billion | ▼ -0.2 pp |
| 2016 | 0.6% | NT$28.05 Million | NT$4.82 Billion | ▼ -1.1 pp |
| 2015 | 1.7% | NT$76.67 Million | NT$4.49 Billion | — |